tirzepatide fatty liver disease Obesity and Fatty Liver: Connection, Risks, and Treatment Eli Lilly's Tirzepatide Shows Promise

Research into tirzepatide alone demonstrates robust weight loss outcomes: clinical trials showed average reductions of 2022% body weight over 68 weeks in patients with obesity

Peptides with half-lives of 1224 h may be viable with twice-daily dosing or if other enabling properties (very high potency, very wide therapeutic window) partially compensate

Owji AA, Khoshdel Z, Sanea F et al (2002b) Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus

You can still use semaglutide if you have diabetic retinopathy, but you need careful monitoring and possibly a slower dose increase

Mol Metab (2019) 30:72130

Targeting aging with metformin (TAME)